NCT00881621 2025-03-03
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Phase 2 Terminated
Clinical Trials
49 trialsNCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01199367 2024-04-25
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT00251433 2023-03-31
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
Phase 1 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT00508274 2021-09-21
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Novartis
Phase 3 Terminated
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT01264081 2019-11-13
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00759642 2019-07-01
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
University of Kansas Medical Center
Phase 2 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT00225758 2018-07-27
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT01934894 2017-07-02
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01868503 2017-06-26
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Stanford University
Phase 2 Terminated
NCT00496366 2017-03-21
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00490061 2017-03-06
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Stanford University
Phase 2 Terminated
NCT01123473 2016-10-12
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01769508 2016-06-13
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT01497626 2016-02-17
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Phase 1 Terminated
NCT01534455 2016-02-10
Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
GBG Forschungs GmbH
Phase 2 Terminated
NCT02131506 2016-02-02
CAELYX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1 Terminated
NCT01495884 2015-10-26
The Myocet/Lapatinib Study. ICORG 10-03, V5
Cancer Trials Ireland
Phase 1/2 Terminated
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00754702 2015-09-28
Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
University Hospital of Crete
Phase 2 Terminated
NCT01161368 2015-08-13
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
Central European Cooperative Oncology Group
Phase 2 Terminated
NCT00857714 2015-07-08
Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
Indiana University
Phase NA Terminated
NCT01427322 2015-07-08
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Virginia Commonwealth University
Phase EARLY_PHASE1 Terminated
NCT01666431 2014-12-03
Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment
University of Zurich
Phase 2 Terminated
NCT01238029 2014-11-21
CELAVIE
Sponsor GmbH
Phase 1 Terminated
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00709618 2014-07-14
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
Phase 2 Terminated
NCT01145404 2014-07-02
GastroLap
National Center for Tumor Diseases, Heidelberg
Phase 2 Terminated
NCT01477060 2014-02-20
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
Fondazione Michelangelo
Phase 2 Terminated
NCT00903656 2013-12-24
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Terminated
NCT01705340 2013-09-30
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01658358 2013-02-27
ErbB2 Positive Metastatic Breast Cancer
China Medical University Hospital
Phase 1/2 Terminated
NCT01245660 2013-01-11
LAPAINBLAD
University Hospital, Bordeaux
Phase EARLY_PHASE1 Terminated
NCT00499681 2012-08-10
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00820924 2012-03-28
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
GlaxoSmithKline
Phase 2 Terminated
NCT00657137 2012-03-15
APRiCOT-B
Tragara Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00317434 2009-12-15
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Terminated
NCT00888810 2009-04-28
TOPO-LAPA
Centre Francois Baclesse
Phase 2 Terminated
NCT00239200 2008-07-30
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Terminated